Skip to main content
Celyad Oncology SA logo

Celyad Oncology SA — Investor Relations & Filings

Ticker · CYAD ISIN · BE0974260896 LEI · 549300ORR0M8XF56OI64 BR Professional, scientific and technical activities
Open in API
Filings indexed 923 across all filing types
Latest filing 2026-04-02 Annual Report
Country BE Belgium
Listing BR CYAD

About Celyad Oncology SA

https://celyad.com/

Celyad Oncology is a biotechnology company primarily focused on unlocking the potential of its intellectual property in the field of cell therapy. The company discovers and develops innovative technologies for Chimeric Antigen Receptor T-cell (CAR-T) therapies aimed at treating cancer. Its differentiated strategy includes the advancement of proprietary technology platforms and CAR T-cell candidates designed to broaden the range of treatable cancer indications and overcome the main limitations of existing CAR T-cell therapies.

Recent filings

Filing Released Lang Actions
FINAL Celyad_English_ARA 2025_Final 20260402.pdf
Annual Report Classification · 100% confidence The document is titled 'Annual Report 2025' for Celyad Oncology and contains extensive sections typical of a full annual report, including a detailed activity report, corporate governance, group structure, shareholding, share capital, consolidated financial statements, notes to the financial statements, and a shareholder letter. It includes comprehensive financial data, management discussion, risk analysis, governance, remuneration, and auditor's report. The length is substantial (15,000 characters) and the content is consistent with a full yearly report covering company activity and financial performance for the fiscal year ending December 31, 2025. There is no indication that this is merely an announcement or a summary; it is the full report itself. Therefore, the appropriate classification is Annual Report (10-K). FY 2025
2026-04-02 English
FINAL Celyad_French_ARA_2025-Final 20260402.pdf
Annual Report Classification · 95% confidence The document is a comprehensive “Rapport d’Activité” (French for Annual Report) for the year ending December 31, 2025. It includes business overview, strategy, governance, remuneration report, group structure, shareholder information, full consolidated financial statements (balance sheet, income statement, cash flows) and detailed notes. This is not a brief announcement or certification; it is the full annual report itself. Therefore, it matches the Annual Report category. FY 2025
2026-04-02 French
celyadoncology-2025-12-31-1-en.xhtml
Annual Report Classification · 100% confidence The document text includes multiple indicators that it is a comprehensive annual report. It contains sections such as "LETTRE AUX ACTIONNAIRES" (Letter to Shareholders), "RAPPORT D’ACTIVITÉ" (Activity Report), detailed financial analyses for the fiscal year ending December 31, 2025, governance information including board composition and remuneration policies, risk management, group structure, shareholder information, and consolidated financial statements with auditor's report. The presence of detailed financial statements and notes confirms it is a full annual report rather than a summary or announcement. The document length is substantial (15,000 characters), supporting that it is the full report and not just an announcement. Therefore, the appropriate classification is Annual Report (10-K). FY 2025
2026-04-02 French
celyadoncology-2025-12-31-1-en.xbri
Annual Report
2026-04-02 French
Final clean 20260402_CYAD - PR FY Financial Results 2025 EN (5) DGEO BDO.pdf
Annual Report Classification · 95% confidence The document is a press release titled "Celyad Oncology reports full year 2025 financial results and business highlights" dated April 2, 2026. It contains detailed financial data for the full fiscal year ended December 31, 2025, including revenue, expenses, profit/loss, cash flow, and balance sheet figures. It also discusses operational highlights, going concern issues, and audit confirmation by the statutory auditor. The document includes comprehensive financial statements and management commentary on the financial results and business status. The document is over 12,000 characters, indicating it is a full report rather than a brief announcement. The presence of full-year financial results, detailed financial tables, and audit commentary aligns with the characteristics of an Annual Report (10-K equivalent). Although it is presented as a press release, the depth and breadth of financial information and the inclusion of audit opinion references indicate it is the actual annual financial report content rather than just an announcement of the report's publication. Therefore, the document should be classified as an Annual Report (10-K). FY 2025
2026-04-02 English
Final clean 20260402_CYAD - PR FY Financial Results 2025 FR (5) DGEO BDO.pdf
Annual Report Classification · 95% confidence The document is a detailed financial communication from Celyad Oncology presenting the full financial results for the fiscal year ended December 31, 2025. It includes comprehensive financial statements such as the consolidated income statement, balance sheet, and cash flow statement, along with detailed narrative on operational highlights, financial performance, and outlook. The document also references the upcoming publication of the full annual report and audit opinion. The length (over 14,000 characters) and the presence of substantive financial data and analysis confirm this is the actual annual financial report rather than a brief announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K). FY 2025
2026-04-02 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.